Physician profile
Jewel Johl
NPI 1407852858
$297,738.64
in general payments reported to CMS, 2019-2025
89 companies · $51K in 2025
The $51K reported for 2025 was more than what 97% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $23K · 2020: $17K · 2021: $42K · 2022: $34K · 2023: $76K · 2024: $55K · 2025: $51K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $111K · Consulting Fee: $40K · Food and Beverage: $17K · Travel and Lodging: $10K · Honoraria: $2,975 · Education: $316 · Long Term Medical Supply Or Device Loan: $99.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $110,695.00 |
| Consulting Fee | $40,299.10 |
| Food and Beverage | $16,940.29 |
| Travel and Lodging | $10,398.75 |
| Honoraria | $2,975.00 |
| Education | $315.82 |
| Long Term Medical Supply Or Device Loan | $99.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $119,220.07 | 2019-2025 | Opdivo |
| Astrazeneca Pharmaceuticals Lp | $46,410.07 | 2019-2025 | Calquence, Imfinzi, Enhertu |
| Mirati Therapeutics, INC. | $41,998.91 | 2023-2024 | Krazati |
| Takeda Pharmaceuticals U.S.A., INC. | $18,475.36 | 2019-2025 | Fruzaqla, Iclusig, Ninlaro |
| Jazz Pharmaceuticals INC. | $13,175.18 | 2020-2025 | |
| Abbvie INC. | $8,819.63 | 2019-2025 | |
| Genentech USA, INC. | $8,409.15 | 2019-2025 | Polivy, Lunsumio, Columvi |
| Amgen INC. | $7,727.78 | 2019-2025 | Nplate, Lumakras, Evenity |
| Celgene Corporation | $4,193.15 | 2019-2025 | Reblozyl, Pomalyst, Opdualag |
| Incyte Corporation | $4,037.08 | 2020-2025 | Jakafi, Monjuvi, Niktimvo |
| Geron Corporation | $2,610.42 | 2025 | Imetelstat, Rytelo |
| Janssen Biotech, INC. | $2,484.27 | 2019-2025 | Darzalex, Erleada, Rybrevant |
| Astrazeneca Uk Limited | $2,220.00 | 2021 | |
| Seagen INC. | $2,058.06 | 2019-2025 | Padcev |
| Genmab U.S., INC. | $1,650.74 | 2025 | Epkinly |
Show all 88 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beone Medicines USA, INC. | $1,513.47 | 2025 | Brukinsa, Tevimbra |
| Bayer Healthcare Pharmaceuticals INC. | $1,237.36 | 2019-2025 | |
| Rigel Pharmaceuticals, INC. | $1,219.47 | 2020-2025 | Gavreto, Tavalisse, Rezlidhia |
| Puma Biotechnology, INC. | $1,204.84 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $865.42 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Pfizer INC. | $729.29 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $676.73 | 2019-2025 | |
| Genzyme Corporation | $474.99 | 2019-2025 | |
| Array Biopharma INC | $429.24 | 2019-2025 | Mektovi, Braftovi, Tukysa |
| Astellas Pharma US INC | $344.38 | 2019-2025 | Xtandi, Padcev, Vyloy |
| Daiichi Sankyo INC. | $344.32 | 2022-2025 | Enhertu, Injectafer, Datroway |
| Kite Pharma, INC. | $336.69 | 2020-2025 | Yescarta |
| Glaxosmithkline, LLC. | $266.58 | 2022-2025 | Jemperli, Zejula, Ojjaara |
| Genentech, INC. | $260.54 | 2019-2025 | Lunsumio, Columvi |
| Gilead Sciences, INC. | $256.12 | 2019-2025 | Trodelvy |
| Exelixis INC. | $251.44 | 2019-2025 | Cabometyx |
| Lilly USA, LLC | $224.66 | 2019-2025 | Jaypirca, Verzenio |
| Eisai INC. | $194.53 | 2022-2025 | |
| Pharmacyclics LLC, An Abbvie Company | $173.74 | 2019-2023 | Epkinly |
| Springworks Therapeutics, INC. | $154.86 | 2024-2025 | Ogsiveo, Gomekli |
| Karyopharm Therapeutics INC. | $149.11 | 2024-2025 | Xpovio |
| Sobi, INC | $135.11 | 2023-2025 | |
| Telix Pharmaceuticals | $134.45 | 2025 | Illuccix |
| Alexion Pharmaceuticals, INC. | $126.66 | 2025 | Ultomiris |
| Nevro Corp. | $126.62 | 2019 | |
| Pharmaessentia USA Corporation | $125.27 | 2025 | Besremi |
| Agios Pharmaceuticals, INC. | $122.37 | 2024-2025 | Pyrukynd |
| Stemline Therapeutics INC. | $117.51 | 2025 | Orserdu |
| Adc Therapeutics America, INC. | $114.42 | 2024-2025 | |
| Servier Pharmaceuticals LLC | $109.07 | 2025 | |
| Taiho Oncology, INC. | $104.66 | 2023-2025 | |
| Coherus Oncology, INC. | $100.73 | 2024-2025 | Loqtorzi |
| Syndax Pharmaceuticals, INC. | $95.31 | 2025 | |
| Tersera Therapeutics LLC | $94.09 | 2019-2025 | Zoladex |
| Emd Serono, INC. | $85.07 | 2021-2025 | Tepmetko |
| Recordati_rare_diseases_inc. | $77.95 | 2023-2025 | Sylvant |
| Aveo Pharmaceuticals, INC. | $76.08 | 2025 | |
| Myriad Genetic Laboratories, INC. | $70.31 | 2019-2024 | Precisetumor, Prolaris |
| Sumitomo Pharma America, INC. | $68.23 | 2023-2025 | Orgovyx |
| Novocure INC. | $66.63 | 2020-2025 | Optune Gio, Optune |
| Spectrum Pharmaceuticals INC. | $62.39 | 2024-2025 | Rolvedon |
| Ipsen Biopharmaceuticals, INC | $61.07 | 2024-2025 | Onivyde |
| Pharmacosmos Therapeutics INC. | $53.56 | 2025 | Monoferric |
| Deciphera Pharmaceuticals INC. | $53.37 | 2024-2025 | Qinlock, Romvimza |
| Invivyd INC | $44.08 | 2025 | Pemgarda |
| Tactile Systems Technology INC | $41.00 | 2023-2024 | Entre Plus, Flexitouch Plus |
| Azurity Pharmaceuticals, INC. | $38.67 | 2024-2025 | Danziten, Vivimusta |
| Alnylam Pharmaceuticals INC. | $37.62 | 2023 | Givlaari |
| Boehringer Ingelheim Pharmaceuticals, INC. | $36.13 | 2025 | |
| Iovance Biotherapeutics, INC. | $34.95 | 2025 | Amtagvi |
| Beigene USA, INC. | $34.84 | 2025 | Tevimbra |
| Sun Pharmaceutical Industries INC. | $33.99 | 2019-2025 | |
| Caris Mpi, INC. | $28.37 | 2025 | Mi Cancer Seek |
| Kyowa Kirin, INC. | $27.97 | 2025 | |
| Acrotech Biopharma INC. | $27.86 | 2022 | |
| Blueprint Medicines Corporation | $26.05 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $25.99 | 2025 | Libtayo |
| Tesaro, INC. | $25.85 | 2019 | |
| Immunocore Limited | $23.41 | 2025 | Kimmtrak |
| Myovant Sciences INC. | $22.88 | 2022 | |
| Foundation Medicine, INC. | $22.69 | 2023 | |
| Nuvation Bio INC. | $21.85 | 2025 | Ibtrozi |
| Fennec Pharmaceuticals, INC. | $21.79 | 2025 | Fyarro |
| Argenx US, INC. | $21.77 | 2024 | Vyvgart Hytrulo |
| Legend Biotech USA INC. | $21.27 | 2025 | Carvykti |
| Progenics Pharmaceuticals, INC. | $20.04 | 2025 | |
| Clovis Oncology, INC. | $19.73 | 2019 | |
| Octapharma USA, INC. | $19.52 | 2023 | Octagam Immune Globulin (Human) |
| Cti Biopharma Corp. | $18.69 | 2023 | Vonjo |
| Amag Pharmaceuticals, INC. | $17.72 | 2020 | |
| Janssen Pharmaceuticals, INC | $15.99 | 2025 | |
| Napo Pharmaceuticals INC | $15.49 | 2025 | Gelclair Concentrated Oral Gel |
| Accord Healthcare, INC. | $13.85 | 2025 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$1,117.91 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jewel Johl listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.